Nivolumab plus chemo for young people with nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests combining the immunotherapy drug nivolumab with standard chemotherapy to treat newly diagnosed nasopharyngeal cancer in children and young adults. The goal is to see if adding this immune-boosting medicine can help shrink tumors and prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 21 years old or younger.
- You must have newly diagnosed nasopharyngeal cancer (NPC) that has not spread to distant parts of the body, and it must be stage II, III, or IV.
- You should be able to do most of your normal daily activities (doctors call this a performance status of 60% or higher).
- Your blood counts (like white blood cells and platelets) and organ function (kidney, liver, heart) need to be within certain ranges.
- If you have HIV, hepatitis B, or hepatitis C, the virus must be under control with treatment.
- You cannot have had chemotherapy or radiation for any cancer in the last 3 years, or have an autoimmune disease that required strong medicines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the immunotherapy drug nivolumab (Opdivo) can help treat nasopharyngeal cancer in both children and adults. It is for people who have just been diagnosed and have not yet received any cancer treatment.
This trial tests a new combination of an immunotherapy drug (tislelizumab) plus standard chemoradiotherapy for people with advanced nasopharyngeal carcinoma. It aims to find out if this combination is more effective than standard care alone.
This trial compares adding the immunotherapy drug toripalimab to standard chemotherapy (GP) versus chemotherapy alone for children and teens with advanced nasopharyngeal cancer. It aims to see if the combination helps reduce the chance of the cancer coming back.
This trial tests a new combination of immunotherapy (JS001) and chemotherapy (PFLL) versus a standard regimen (GP) for people with nasopharyngeal cancer that has spread. The goal is to see if the new combination works better at controlling the disease.
This trial tests a new immunotherapy drug (serplulimab) given together with standard chemotherapy and radiation for nasopharyngeal cancer that has spread to nearby lymph nodes. It aims to see if adding this drug can help shrink tumors and improve outcomes.
This trial tests a combination of two types of radiation therapy (standard SBRT and low-dose radiation) along with chemotherapy and an immunotherapy drug (PD-1 antibody) for people whose nasopharyngeal cancer has come back or spread. The goal is to see if this combination can better control the cancer.
Hear when a new Stage II Nasopharyngeal Carcinoma AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.